MaxCyte, Inc. (MXCT)

US — Healthcare Sector
Peers: SGHT  CVRX  NPCE  RPID  CNMD  KIDS  SRDX  ITGR  LUNG  IRMD  OFIX  OSA  ANIK  HSKA 

Automate Your Wheel Strategy on MXCT

With Tiblio's Option Bot, you can configure your own wheel strategy including MXCT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MXCT
  • Rev/Share 0.3556
  • Book/Share 1.8821
  • PB 1.2698
  • Debt/Equity 0.0944
  • CurrentRatio 12.2318
  • ROIC -0.2294

 

  • MktCap 254101299.0
  • FreeCF/Share -0.3111
  • PFCF -7.7101
  • PE -6.0594
  • Debt/Assets 0.0818
  • DivYield 0
  • ROE -0.1989

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MXCT
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Neutral

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.

Read More
image for news MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
MXCT
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive

MaxCyte (MXCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Read More
image for news Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
MXCT
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive

MaxCyte (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Read More
image for news Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
MXCT
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive

MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
MXCT
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

Read More
image for news MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

About MaxCyte, Inc. (MXCT)

  • IPO Date 2021-07-30
  • Website https://maxcyte.com
  • Industry Medical - Devices
  • CEO Mr. Maher Masoud
  • Employees 114

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.